HOPKINTON, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals will present at the Dawson James Securities 2016 Stock Growth Conference on Thursday, October 20th at 10:45 AM Eastern Time at the Wyndham Grand Hotel in Jupiter, Florida. For more information on the conference or for investors to register, please go to DJS Conference. To view the live audio webcast of the presentation please go to http://ir.springbankpharm.com or http://wsw.com/webcast/dawson2/sbph.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. For more information please visit: www.springbankpharm.com.
About Dawson James Securities
Dawson James Securities, Inc., a member of FINRA/SIPC, is a full service investment bank headquartered in Boca Raton, FL. http://www.dawsonjames.com.
Contact: Jon Freve Chief Financial Officer (508) 500-4956 firstname.lastname@example.org
Source:Spring Bank Pharmaceuticals Inc.